60 results about "High dosage" patented technology

A method for treating or reducing a likelihood of hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates utilizes a relative high dose of nasally administered insulin. In one aspect, the method includes intranasally administering, to a neonate in need thereof, an effective dose of insulin comprising between 350 U to 2000 U insulin.

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The pharmaceutical composition comprises gefitinib, erlotinib, afatinib, neratinib, osimertinib and the like which serve as active ingredients. The pharmaceutical composition disclosed by the invention can simultaneously contain various EGFR inhibitors as active ingredients, and the active ingredients are controlled at ultra-low dosage, so that the pharmaceutical composition not only can ensure the treatment effect, even the drug effect of the pharmaceutical composition is obviously superior to that of a high-dosage EGFR inhibitor independent administration group, but also can ensure the safety, and the pharmaceutical composition is suitable for clinical application. And after the active components are combined, a good synergistic effect is achieved, and more importantly, the occurrence of drug resistance can be remarkably reduced or even resisted. In a lung cancer cell culture experiment, the EGFR inhibitor independent administration group has a drug resistance phenomenon at the earliest 20 days, but the pharmaceutical composition group still has no drug resistance phenomenon after 160 days of administration.

A water remediation system and accompanying method includes remediation by reducing the concentration of nutrients in the water and dosing the water with metal ions. It has been found that through a combination of reducing nutrients present in the water and treating with metal ions, the requirement to treat with high chemical dosages is removed.

The invention discloses a screening and dosage determining method of a grape heat resistance inducer, and belongs to the technical field of plant stress resistance physiology and cultivation. The method comprises the following steps: soaking grape leaf wafers in inducers with different concentrations, and carrying out heat treatment under a plurality of temperature gradients; determining a chlorophyll OJIP rapid fluorescence parameter and constructing a heat resistance comprehensive index, and further calculating a normalized relative heat resistance improvement value; fitting a quantitative relation with the concentration by using a single-peak dose-effect model containing a high-dose inhibition item; statistical inference is carried out by adopting Bootstrap resampling, and a stable and effective recommended application concentration in a wide temperature range is finally determined by analyzing a common intersection or a statistical median of effective concentration intervals under multiple temperatures. The method realizes indoor rapid and quantitative screening, can realize quantitative comparison of induction intensity and dose sensitivity of different inducers under a unified evaluation system, and can be used for identifying heat resistance of grapes.

The invention discloses a hexapeptide LR6 with anti-inflammatory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide LR6 is LDAVDR, and the hexapeptide LR6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide LR6 is identified from spirulina platensis proteolysis liquid and has potential interaction with Keap1, an LPS-induced RAW264.7 cell test shows that TNF-alpha, IL-1beta and IL-10 can be remarkably inhibited by treatment of low-dose (200mM) and high-dose (400mM) hexapeptide LR6, the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone, and the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone. Compared with dexamethasone, the hexapeptide LR6 has a better anti-inflammatory effect and can be used for preparing anti-inflammatory drugs.

This invention discloses an ultrafine particle soil fluidized solidifier and an intelligent pile-forming process for in-situ pre-mixed fluidized solidified soil. The solidifier comprises cement, granulated blast furnace slag powder, and other main solidifying materials, along with an organic polymeric dispersant. Through the action of a low dosage of the organic polymeric dispersant, the plastic-to-fluid transition of the cohesive solidified soil is achieved, solving the technological challenges in preparing ultrafine particle fluidized solidified materials with high dosage, low moisture content, and high strength. An innovative airtight construction process is proposed. By introducing a pressurized airflow during mixing, the gas phase space of the ultrafine particle fluidized solidified material is increased, providing space for the growth of hydration product crystals and suppressing the strength-reducing effect of the organic polymeric dispersant on the solidified soil. This achieves rapid mixing of the solidifying material and the solidified soil, significantly improving the construction efficiency of in-situ soil solidification.

A dosing mechanism for a drug delivery device is provided for selecting and dispensing user-variable doses of a medicament. The mechanism includes a housing, a piston rod, and a drive configured to rotate the piston rod and / or a movement application component directly engaged with the piston rod in a dispense rotational direction relative to the housing. A rotational end-stop mechanism terminates dose dispense and includes a first engagement element rotationally fixed to the piston rod and / or the movement application component, and a second engagement element that is constrained against rotation relative to the housing at the end of dose dispense. To improve dose accuracy, the second engagement element remains out of direct engagement with the first engagement element during dispensing, and only at the end of dose dispense directly engages the first engagement element to provide a rotational stop. A drug delivery device incorporating the dosing mechanism is also disclosed.

Aerosolization devices and procedures are described that improve air-jet dry powder inhaler (DPI) technologies and other types of inhalers, thereby optimizing aerosolization performance and expanding dosing capacity. One example device includes a variable-sized aerosolization chamber and an adjustment mechanism that allows the chamber size to be changed between activations. During use, the distance between the aerosolization chamber's air channel and the top of the powder bed remains virtually constant, even as the powder bed empties with each successive activation of the device.

An exhaust aftertreatment system comprises a pump; reagent dosing devices arranged in series with each other; and a controller. The controller comprises a dosing device diagnostic circuit configured to in a first stage measuring a first stage diagnostic indicating an amount of reagent dosed by all the reagent dosing devices, and comparing the measured first stage diagnostic with a nominal first stage diagnostic. If a deviation exceeds nominal performance then in a second stage of evaluation is triggered to identify a faulty reagent dosing device, wherein all the further reagent dosing devices are set to dose at a low quantity while simultaneously activating the first reagent dosing device to dose at two operating points, i.e. at a low dosing quantity and at medium or high dosing quantity and measuring a second stage diagnostic. The measured second stage diagnostic is compared with a nominal second stage diagnostic for determining if the first dosing device is operating correctly or faulty. In a third stage the first reagent dosing device is set to dose at a low quantity while simultaneously only one of the further reagent dosing devices is activated to dose at two operating points, i.e. at a low dosing quantity and at medium or high dosing quantity and a third stage diagnostic is measured and compared with a nominal second stage diagnostic for determining if said only one of said further reagent dosing devices is operating correctly or faulty.

This invention discloses an endothelin A receptor antagonist-albumin fusion protein and its application in preventing and treating hypotension during anesthesia induction. The fusion protein is formed by chemically coupling BQ-123 with human serum albumin (HSA). BQFu significantly enhances its antihypertensive effect by prolonging the half-life of BQ-123 and improving plasma stability. Experiments show that BQFu dose-dependently inhibits the decrease in mean arterial pressure (MAP) in a propofol-induced hypotension model, with a sustained and stable effect in the high-dose group (30 mpk), shortening the recovery time to 20.8 ± 10.5 min, while maintaining BQ-123 activity. This invention provides a long-acting and safe prevention and treatment strategy for hypotension during anesthesia induction.

The utility model discloses an antibacterial softener storage and use device with an accurate proportioning structure, and aims to provide the antibacterial softener storage and use device with the accurate proportioning structure, which has the advantages that the taking convenience is improved, and the dosage precision is high. The device comprises a base; the bracket is connected with the base; the storage box is connected with the support, and the storage box is connected with a switch assembly; the material receiving assembly is connected with the base, the material receiving assembly is provided with a quantifying cup, and a quantifying plate is movably connected with the base; and the ratio control assembly is connected with the support, the ratio control assembly is provided with a material return pipe, and the material return pipe is connected with the storage box and the quantitative cup. The device has the beneficial effects that various raw materials of the antibacterial softening and moistening agent can be quickly discharged in the device through the storage device, and meanwhile, the quantity can be accurately controlled; accurate control of the proportion is realized; the structural connection and operation stability is improved, and feeding and discharging are convenient to store; the operation efficiency is improved.

The invention relates to a traditional Chinese medicine preparation, in particular to application of a compound live brain soothing capsule in preparation of a medicament for treating insomnia. The dosage of the medicine is 200 mg / kg. Experiments show that the sleep improvement effect of the compound Shuonaoshu capsule on an anesthesia reviving experiment evaluation test medicine, a high-dose group (200 mg / kg) of the compound Shuonaoshu capsule can effectively prolong sleep time, dose dependence exists, sleep quality can be moderately improved, the higher the concentration is, the more obvious the improvement effect is, and the more obvious the effect is. The invention reveals that the compound Liangjinshu capsule has a treatment effect on insomnia, and is expected to provide a certain experimental basis for the development of new drugs for insomnia.

Provided are formulations and methods to treat ultra-potent synthetic opioid overdose with high dose Naloxone formulations comprising naloxone hydrochloride or a pharmaceutically acceptable salt thereof, one or more preservatives, one or more buffering agents, a tonicity modifier, and optionally a pH modifier.

This invention discloses a universal method and composition for solving the pilling problem in cold-formulated cosmetics. Adding an effective amount of glyceryl oleate, citrate / caprylic / capric triglyceride to a cosmetic composition containing a pilling-prone cold-formulated emulsifier can significantly reduce or eliminate pilling. This substance has been discovered for the first time to have a novel anti-pilling application, effective against pilling caused by the emulsifier's own characteristics, high dosage, electrolyte interference, or the addition of large molecules, and is universally applicable to different types of cold-formulated emulsifier systems. This invention is particularly suitable for systems using electrolyte-rich natural plant extracts as the aqueous phase, fundamentally solving the pilling problem and providing a reliable solution for preparing high-feel, all-natural cold-formulated cosmetics.

The present application relates to a kind of tetrahydroxy bile acid pharmaceutical composition and its preparation method and application.The present application provides a kind of pharmaceutical composition, it includes 100 weight parts of compound shown in formula I and 300~900 weight parts of saccharide.The present application also provides the use of the pharmaceutical composition in the preparation of drug for treating PFIC.The pharmaceutical composition of the present application can improve dose accuracy, solve the problem of poor taste of bile acid compound, easy to swallow, can improve the compliance of children drug.The pharmaceutical composition of the present application has good stability, easy to transport and store.In addition, the pharmaceutical composition of the present application realizes the stability of treatment effect under different doses, easy to accurately dose children according to body weight, while having good bioavailability, can realize good absorption and utilization in vivo.

The invention discloses an application of 3 '-sialic acid lactose in preparation of a medicine for treating Alzheimer's disease. The invention further discloses application of the 3 '-sialic acid lactose or the medicinal salt thereof in preparation of a medicine for inhibiting Tau protein aggregation, and a medicinal composition containing the 3'-sialic acid lactose. The specific sialic acid derivative can effectively block pathological aggregation of tau, and the treatment effect of the medicine on AD is remarkably improved. The 3, 3 '-sialic acid lactose is low in acute toxicity, has no genetic toxicity and reproductive toxicity after being taken for a long time at a high dosage, and has relatively good medicinal safety and relatively good medicinal prospects.

The invention relates to application of autophagy in preparation of drugs or health food for improving fluorine-induced neurotoxicity from grape seed procyanidine. Rat and SH-SY5Y cell experiments are carried out, and the rat experiments prove that after intervention of different doses of GSPE, the SOD activity and the GSH content are improved, the MDA level is reduced, the antioxidant capacity of rats is recovered, autophagy is promoted, the filial generation learning and memory retention capacity is remarkably recovered, the autonomous activity capacity is recovered, anxiety behaviors are reduced, the occurrence and development processes of dental fluorosis are slowed down, and the occurrence and development of dental fluorosis are promoted. The change trends of different doses of GSPE present dose dependence, and the protection effect of a high-dose combined intervention group is most significant; in an SH-SY5Y cell experiment, the activity of the cells is improved through GSPE pretreatment, the expression quantity of cleave-caspase3 and cleaved-PARP is remarkably reduced, the autophagy process of the SH-SY5Y cells is promoted, and then the neurotoxicity caused by NaF is relieved. NaF is used as a representative, the prevention and treatment effects of GSPE on the fluorine-induced neurotoxicity are researched, and it is proved that GSPE can inhibit the NaF-induced neurotoxicity, so that the application of autophagy in preparation of drugs or health food for improving the fluorine-induced neurotoxicity from grape seed procyanidine is provided.

This invention relates to the field of concrete, and more particularly to a low-carbon concrete with a high dosage of industrial solid waste and its preparation method. By weight, its components include: cement: 170 parts; fly ash: 170 parts; fine aggregate: 600-800 parts; coarse aggregate: 1000 parts; water: 132 parts; polycarboxylate superplasticizer: 1 part; and modified material MIL53(Al-Fe)@SiO2: 1-5 parts. The invention prepares the MIL53(Al-Fe)@SiO2 modified material through in-situ conversion of fly ash and waste aluminum foil, and applies it to a 1:1 cement-fly ash high-dosage solid waste system. This method maintains high strength above 50 MPa and stable mechanical properties while significantly enhancing the density of the concrete, reducing chloride ion permeability from 0.34% to 0.18%, a reduction of 47.1%. This invention not only realizes the high-value utilization and low-carbon emission reduction of industrial solid waste, but also significantly improves the durability of concrete in harsh environments, and has significant environmental protection and engineering application value.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.

The disclosure provides methods to reverse or regress fibrosis and / or liver cirrhosis in a subject in need thereof, using high-dose (pharmacologic) niacin, or a niacin analog thereof.

The invention provides an efficient oil-soluble paraffin remover and inhibitor as well as a preparation method and application thereof, and the efficient oil-soluble paraffin remover and inhibitor is mainly prepared from the following raw materials in parts by mass: 20-35 parts of oil-soluble polyether, 15-25 parts of a modified olefin copolymer, 5-12 parts of alkylbenzene sulfonate, 3-8 parts of fatty alcohol-polyoxyethylene ether, 8-15 parts of a cosolvent, 2-5 parts of a corrosion inhibitor and a proper amount of base oil. According to the efficient oil-soluble paraffin remover and inhibitor disclosed by the invention, a good paraffin remover and inhibitor effect can be ensured, and cost increase caused by too high dosage can be avoided; and the application range is wide, and the crude oil extraction requirements under different wax content and temperature conditions can be met.

Described herein are pharmaceutical compositions comprising high doses of (Z)-endoxifen. A high dose endoxifen composition may be formulated to prevent crosslinking between the endoxifen active pharmaceutical ingredient and a surrounding layer, such as a capsule. The compositions may be further formulated as enteric resistant compositions for oral administration and delivery to an intestine of a subject. Also described herein are methods of treatment using high dose endoxifen compositions.

The invention discloses a weeding composition and a preparation method thereof. The weeding composition is prepared from the following components in percentage by weight: 10.5 to 31.5 percent of butralin, 10 to 30 percent of s-metolachlor, 5 to 10 percent of clomazone, 10 to 30 percent of compound emulsifier and the balance of compound solvent. The weeding composition provided by the invention can effectively prevent and remove annual weeds in a tobacco field, is safe to tobacco, high in preparation stability, long in weed closing time, low in dosage and very high in market value, and solves the problems of poor safety, short lasting period, high dosage and the like in the process of preventing and removing the annual weeds in the tobacco field by using an existing medicament.

The invention provides application of andrographolide in promoting calf growth and relieving weaning stress based on a microbial community regulation effect, and belongs to the technical field of animal feeding. The andrographolide (AG) can significantly improve the growth performance and the health level of the calves, relieve the weaning stress of the calves and improve the respiratory tract health of the calves by inhibiting inflammation and oxidative stress and systematically regulating and controlling microbial communities at multiple parts. Under the low-dosage feeding level, AG is more prone to optimizing rumen microflora, rumen is promoted to turn to an efficient propionic acid type fermentation mode, and sustainable benefits are achieved; and under a high dosage level, AG exerts a stronger anti-inflammatory and anti-oxidation effect to realize short-term benefit maximization. AG is added, so that the cross-site interaction between microbial communities in the digestive tract and the nasal cavity is enhanced, the colonization of various potential pathogens in the nasal cavity is remarkably inhibited, and the respiratory tract health of the calf is improved.

The present invention discloses a method for adjusting dose parameters, comprising the following steps: Step 1, using TPS to obtain an initial DVH curve of a target area and an organ at risk; Step 2, performing a functional transformation on the obtained DVH curve: performing a feature transformation on the DVH curve; the feature transformation comprises the following two steps: Step 21, reducing the dimension of the functional data using a basis expansion method; Step 22, integrating the data after the dimension reduction process; Step 3, learning the distribution of execution actions through a neural network; Step 4, establishing a reinforcement learning model: using the obtained feature vector as the input of the reinforcement learning model for training, ultimately completing the decision-making process, and obtaining a series of output actions. The present invention first performs a feature transformation on the DVH curve, and then uses the transformed vector as the input of the reinforcement learning model, so that the feature information in the DVH curve is fully mined, thereby improving the accuracy of dose adjustment.

The present invention describes the combination of a 5HT3-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of 5 pramipexole and to enable the use of high doses of pramipexole, useful for treating depressive disorders such as major depressive disorder 54 20 24 20 41 79 19 J un 2 02 4 J u n 2 0 2 4 A B S T R A C T 2 0 2 4 2 0 4 1 7 9 1 9

The present invention relates to a method of loading sotalol intravenously that starts with the highest approved doses, evaluates the QTc effects, and selects the highest does that is represented by a maximum serum drug concentration that does not excessively prolong the QTc interval on the electrocardiogram. The method further relates to down titration if needed.